Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Change in Accured Expenses (2016 - 2017)

Tenax Therapeutics' Change in Accured Expenses history spans 8 years, with the latest figure at $172693.0 for Q4 2017.

  • For Q4 2017, Change in Accured Expenses fell 85.92% year-over-year to $172693.0; the TTM value through Dec 2017 reached -$5.0 million, down 363.63%, while the annual FY2025 figure was -$421000.0, 180.5% down from the prior year.
  • Change in Accured Expenses for Q4 2017 was $172693.0 at Tenax Therapeutics, up from -$1.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.9 million in Q1 2016 and bottomed at -$2.9 million in Q2 2017.
  • The 5-year median for Change in Accured Expenses is -$577929.5 (2013), against an average of -$233547.8.
  • The largest YoY upside for Change in Accured Expenses was 278.16% in 2015 against a maximum downside of 1683.32% in 2015.
  • A 5-year view of Change in Accured Expenses shows it stood at -$710135.0 in 2013, then surged by 347.54% to $1.8 million in 2014, then tumbled by 170.79% to -$1.2 million in 2015, then soared by 198.56% to $1.2 million in 2016, then tumbled by 85.92% to $172693.0 in 2017.
  • Per Business Quant, the three most recent readings for TENX's Change in Accured Expenses are $172693.0 (Q4 2017), -$1.3 million (Q3 2017), and -$2.9 million (Q2 2017).